New developments in long-term treatment of HIV: The honeymoon is over

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 9, 2001, Pages 804-807

  Isada, Carlos M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MITOCHONDRION; PREDICTION; PROPHYLAXIS; PUBLIC HEALTH SERVICE; UNITED STATES; VIRUS LOAD;

EID: 0034839851     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.9.804     Document Type: Article

References (11)

1. Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators. Ann Intern Med 2000; 132:201-205.
2. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342.1085-1092.
3. Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133:493-503.
4. U.S. Public Health Service and Infectious Diseases Society of America. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. MMWR 1999; 48(Aug 20): No. RR-10.
5. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93.
6. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HlV-1 therapy, the VIRADAPT randomised controlled trial. Lancet. 1999 Jun 26; 353:2195-2199.
7. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www.hivatis.org. Accessed April 23, 2001.
8. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
9. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors Ann Intern Med 1999; 131:1548.
10. Dubé MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the adult ACTG Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31:1216-1224.
11. Falusi OM, Abery JA. HIV and cardiovascular risk factors. AIDS Reader 2001; 11(5):253.